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Breast cancer is one of the human cancers where therapeutic
use of radiation has evolved dramatically over the past cen-
tury. The journey is eventful which started with brachytherapy
and still continuing in parallel to the most modern external
beam radiation techniques. Slowly but steadily the use of fas-
cinating sophisticated external beam radiation techniques is
getting a foothold. Though parallel opposed tangent beams
are considered standard technique till now, use of conformal
radiotherapy with its full array including intensity modulation,
image guidance, respiratory motion management and stereo-
taxy are in vogue and gaining pace. Whereas tangent beam is
simple and easy to deliver, many of the new techniques are
complex, time consuming, difﬁcult to implement in large vol-
ume centers and not without risk of uncertainty. The resultant
gain in therapeutic advantage is often questioned and associ-
ated risk of long term radiation damage from the newer tech-
niques due to their inherent nature is promulgated as a major
deterrent for their use.
It took a long time to establish the role of radiation as an
essential component in adjuvant treatment of breast cancer.
Radiation after BCS (Breast Conserving Surgery) for early
as well as locally advanced tumor after neoadjuvant
chemotherapy (NACT) is now considered as an integral part
of BCT (Breast Conserving Therapy) whereas postmastectomy
radiation (PMRT) to chest wall and or regional area is consid-
ered beneﬁcial for a select group of high risk patients [1–5].
This group comprises of patients with four or more node pos-
itive diseases, extranodal extension of tumor, chest wall inva-
sion by tumor, presence of tumor at the resection margin or
having lymphovascular space invasion. The role of radiation
in 1–3 positive nodes after mastectomy has always been an
area of debate. However, a recent meta-analysis supports the
use of radiation for this patient group also [6]. The meta-
analysis conclusively supports beneﬁcial role of postmastec-
tomy radiation in patients with 1–3 positive nodes to reduce
recurrence and breast cancer mortality.
In a very interesting multicenter study, patients with posi-
tive sentinel lymph node biopsy were randomized to receive
either axillary radiation or underwent axillary dissection [62].
Patients receiving axillary radiation showed signiﬁcantly less
arm edema. This will deﬁnitely lead the way for nodal irradia-
tion in future with improved quality of life.
A complex relationship exists between the tumor, its biol-
ogy, host and treatment related parameters which ultimately
dictates curability and thus giving rise to chance of a long term
radiation induced morbidity in survivors. The choice of radia-
tion technique is thus crucial to provide cure and mitigate the
risk of long term complications. 2D planning is still the gold
standard and as technology advanced, 3DCRT, IMRT with
or without simultaneous integrated boost (SIB), arc therapy,
Tomotherapy, stereotactic body radiotherapy (SBRT), and
proton therapy are becoming more crucial for clinical use.
Dosimetric studies are ample in literature and clinical useseems promising. Long term cardiac risk from the effect of
radiation, particularly for left sided breast cancer is a concern
for this favorable group of patients. New technologies are use-
ful in reducing cardiac dose and thus can help in reducing long
term cardiac morbidity and mortality. Another important
breakthrough in the last two decades is establishment of
hypofractionation as standard of care in many developed
countries for whole breast radiation as part of BCT. For short-
age of space, different dose fractionation schedule combined
with radiation techniques will be discussed as a whole.History of external beam radiotherapy in breast cancer
The journey of external beam radiation started in the last cen-
tury with superﬁcial X-rays and gradually moved on to high
energy X-rays and photons including radionuclides like
60-Co (radioactive Cobalt) and 37-Cs (Cesium). The revolu-
tion in radiation oncology began post Second World War,
with development of telecobalt followed by high energy linear
accelerator in 1950 s. However it was only in 1960–1970 when
linear accelerators came more into practice for therapeutic
medical indications. This period is thus popularly called mega-
voltage era [7]. Changes were notably apparent in technical
aspects of radiation, starting from manual surface marking
based planning to adoption of computer and software. The
advent of computed tomography (CT) scan in the ﬁeld of radi-
ation oncology further added to the sophistication with its
robust use in simulation, segmentation, dose and inhomogene-
ity correction which all together brought a signiﬁcant change
toward individual patient based planning compared with ear-
lier 2D standard planning techniques. Modern linear accelera-
tors are also equipped with different imaging facilities which
made patient positioning and treatment delivery precise thus
providing the opportunity of reducing target volumes. All of
these essentially lead to a theoretical dogma of less radiation
induced morbidity. Again, for breast cancer, most of which
are detected very early with increased patient awareness, thus
giving rise to the issue of long term survivorship, the use of
new technology must be well planned and thought to avoid
morbid survival. With the ray of hope in sight, thus, toxicity
reduction, notably skin toxicity, cardiac toxicity and ischemic
heart disease, pulmonary toxicity and risk of pulmonary ﬁbro-
sis seem to be manageable and reducible. This again, has been
said with caution, given the young age of these modern tech-
niques and lack of data to prophesize the future.Modern planning and verification
Positioning and breathing motion
Conventionally, radiotherapy to breast is delivered in supine
position with arms abducted beside head. Breast board is used
for selected patients with signiﬁcant chest wall angulation to
make the anterior chest wall horizontal. Selected patients merit
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target coverage adequate. Evidences from both sides of the
Atlantic prove that prone position is suitable particularly for
large volume breasts after wide local excision of tumor
[8–10,25]. However, caution should be exercised to take care
of the CTV-PTV (Clinical Target Volume-Planning Target
Volume) margin. Left sided small volume breast perhaps does
not merit prone position treatment which actually may be
detrimental [9].
Modern 3DCRT, IMRT, VMAT (Volumetric Modulated
Arc therapy) or helical techniques give the freedom of multiple
ﬁeld placement from different angles and thus necessitating
both arms to be placed above head in supine position. Using
breast board, thermoplastic ﬁxation device, head rest or other
immobilization device like VacLok improve setup accuracy.
When setup accuracy was compared between supine on
Vac-LokTM (CIVCO Medical Solutions, IA) versus prone on
prone breast board positions, supine on VacLok immobiliza-Table 1 Description of different CTVs for radiation planning:
Structure Contouring guideline
Whole breast
CTV
Entire mammary gland (apparent CT glandular
tissue) as deﬁned in planning CT scan is contoured
as whole breast CTV. The lumpectomy cavity
should remain within this. Conventionally, the
upper border remains at the insertion of second
rib, lower border at the plane where glandular
tissue disappears which corresponds to the
inframammary fold, lateral border at mid axillary
line excluding the latissimus dorsi muscle and
medial border at sternocostal junction. Anteriorly
the CTV goes up to skin. Posteriorly, it should
exclude pectoralis muscles and ribs along with
chest wall muscles. It is important to understand
that the ﬁnal PTV is created by editing oﬀ 4–5 mm
thick strip of tissue underneath the skin anteriorly
to spare the skin from high dose and to create dose
build-up region. It must be kept in mind that,
clinical and CT deﬁnition of structures should be
complimentary to each other
Lumpectomy
GTV
Deﬁned as the surgical bed, as determined by
surgical clips placed in the lumpectomy cavity
during surgery. Where clips cannot be placed due
to logistic reasons, lumpectomy cavity or seroma
cavity formed after surgery as seen in planning CT
scan should be contoured as the tumor cavity or
lumpectomy cavity
Chest wall
CTV
In contrast to whole breast CTV, chest wall CTV
includes skin, pectoralis muscles, intercostal
muscles and ribs as part of it. Superior border
remains at the caudal end of head of clavicle.
Inferior border lies at the plane of loss of apparent
CT glandular tissue of opposite breast, medial
border lies at sternocostal junction and lateral
border lies at mid axillary line excluding latissimus
dorsi muscle. The costo-pleural interface serves as
the posterior border. Though it is wise to include
mastectomy scar within CTV, it is not always
necessary for scars extending beyond midline
Nodal CTV Interested readers may follow the link provided in
the reference for detailed information. It is beyond
the scope of this article to describe thistion device with headrest and arms over head showed better
setup accuracy compared to the later technique in a series of
patients treated with helical Tomotherapy [11]. The proposed
dosimetric cardiac beneﬁt from prone positioning may be over-
shadowed by the setup uncertainty and requirement for a lar-
ger CTV-PTV margin in this position.
Respiratory gating in the inspiratory phase or Deep
Inspiration Breath Hold (DIBH) technique have been found
effective in reducing irradiated volume of the heart. The idea
is to keep heart out of radiation ﬁeld as much as possible which
is crucial in treating left sided breast cancer. With inspiratory
gating or DIBH, it is possible to reduce V50 of heart signiﬁ-
cantly [12]. This is expected to translate in clinical beneﬁt in
terms of reduced long term cardiac morbidity and mortality.
The overall effect of respiratory gating is thus promising in
modern day breast radiation [13].
Unlike the ﬂuoroscopy guided simulation and manual dose
calculation of previous age, modern day radiotherapy planning
software is capable of visualizing target and organs at risk
(OAR) in three dimension. Options like autosegmentation
and various other contouring tools have made target delin-
eation process easier compared to earlier time. Visualization
of the tumor cavity and or clips at the cavity margins, provide
better cavity delineation and also guides selection of appropri-
ate electron energy and depth when boost is planned with elec-
tron [14–16]. Availability of RTOG (Radiation Therapy
Oncology Group) contouring guideline [17] has made delin-
eation of various structures more systematic, reproducible
and error free. The presence of soft tissue, bone, cartilage, lung
tissues and air cavities in radiation pathway having different
electron densities and thus beam attenuation, give rise to chance
of uncertainties. More recently developed software also pro-
vides the opportunity to correct different tissue inhomogeneities
and calculate dose and monitor units more precisely [7].
Contouring of normal structure and target volume
Earlier, borders of intact breast were used to be deﬁned clini-
cally depending upon standard anatomical landmarks and
clinical extent of palpable breast tissue. The advent of CT
scanners now gave the facility to see the cavity and or the ser-
oma within it, surgical clips at the cavity margins, breast par-
enchyma and non-breast fatty tissues. Whereas, the following
recommendations (Table 1) can be used for delineation of dif-
ferent CTVs, interested readers are requested to follow the link
for more detailed information [17].
Treatment verification
Modern day linear accelerators are equipped with various gan-
try mounted imaging devices for setup veriﬁcation and image
guidance. Most of these treatment veriﬁcation systems are X-
ray based. A conventional X-ray source with opposing ﬂat
panel detector is mounted over the gantry. This gives the ben-
eﬁt of generating kilovoltage Cone Beam CT (kVCBCT) with
high image resolution. The megavoltage X-ray source of the
linear accelerators can also be used with an opposing ﬂat panel
detector (EPID) for image veriﬁcation purpose. This
MVCBCT has the advantage of using same source of radiation
for treatment and imaging, thus avoiding uncertainty of arti-
fact and needs to extrapolate attenuation coefﬁcient, albeit
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dimensional images are acquired with rotation of the X-ray
source around the target and further reconstruction. Use of
respiratory gating technology has become more common for
thoracic radiation to make treatment delivery further precise.
Four dimensional CT scan and Real Time Tumor Tracking
are few examples of this method. These technologies have
not only revolutionized radiation delivery precision, but also
given the chance to reduce the CTV-PTV margin and effec-
tively reduced normal tissue toxicity. Additional radiation
dose from frequent X-ray based imaging has been a concern
of second malignancy [18] thus giving way to MR based image
guidance systems.
Incorporation of all these methods has brought into prac-
tice newer radiation delivery technologies. This article brieﬂy
describes the current advances pertaining to external beam
radiation therapy techniques in breast cancer.
New techniques
Three dimensional conformal radiotherapy (3D-CRT)
With the availability of better computerized treatment plan-
ning system, it has become easier to generate multiple plans
for a given patient. One of the most serious concerns of breast
radiotherapy is long term cardiac toxicity. The risk of long
term major cardiac complications are linearly increased with
mean heart dose and an estimated risk of 7.4% was found with
every 1 Gy mean dose increment to the heart [19]. In a recent
analysis of a cohort of cancer patients from Sweden, treated
between 1970 and 2003, a detailed angiographic mapping of
stenosed cardiac vessels was done with respect to radiation
portals. This study has shown signiﬁcant association between
radiation and cardiac stenosis location [54]. In a dosimetric
study from India by Roy et al. [55], dose to left anterior
descending coronary artery (LADCA) and left circumﬂex
coronary artery (LCx) was analyzed for early breast cancer
patients treated either with conservative surgery or mastec-
tomy. Data were analyzed to see any difference with left or
right sided tumor. The authors demonstrated an increased
dose to LADCA irrespective of the nature of surgery (conser-
vation/mastectomy). These along with numerous other studies
have demonstrated risk of increased cardiac dose leading to
perfusion defect and risk of long term cardiac morbidity and
mortality [56,57]. Over the years conformal radiotherapy has
given an edge over conventional radiotherapy to minimize car-
diac dose. Various combination of gantry angles, number of
ﬁelds including ﬁeld in ﬁeld (FiF), beam weightage, wedge pair
combination, multi leaf collimator (MLC) positioning and dif-
ferent energy combination, are some of the effective ways to
reduce heart dose with 3DCRT [13,20–24]. With effective
implementation of cardiac protective radiation techniques,
dose to left side of heart has been reduced compared to earlier
time [58].
With conventional 2D tangential beam technique, covering
entire breast parenchyma sometimes becomes impossible. This
problem can be overcome using conformal technique. To
avoid inadequate target coverage due to respiratory motion,
anterior border of ﬁeld is usually placed 1.5–2 cm anterior to
the skin to accommodate the breast during its respiratory
excursion. Mechanical block of heart and lung is possible byMLC positioning reducing cardiac and lung volume within
radiation beam. 3D plan was found to be dosimetrically supe-
rior compared to standard 2D plan in a study by Aref et al. in
85 patients with intact breast [25]. Multiﬁeld conformal radio-
therapy has the risk of greater volume of normal tissue receiv-
ing low dose of radiation which is of particular concern for
second malignancy.
The recent surge seen with use of 3DCRT is attributed to
more number of patients being treated with accelerated partial
breast irradiation (APBI). Published data have shown APBI
as a feasible technique with local control, toxicity and cosmesis
comparable to standard APBI techniques like interstitial
implant. In fact, the rise of 3DCRT followed after one of the
early studies fromWilliamBeaumontHospital showed that lim-
ited ﬁeld radiation after breast conservation is comparable in
terms of local control [26]. Even with prone position APBI,
3DCRT was feasible and provided comparable tumor control
with additional beneﬁt of heart and lung being completely
spared out of the radiation ﬁeld [27–29]. Multiple other studies
have also shown acceptable acute and late toxicity with compa-
rable tumor control using 3DCRT APBI. However, one study
has also reported increased late toxicity and poor cosmesis from
3DCRTAPBI [30].When comparedwith proton beamAPBI, in
a phase1 study, 3DCRTAPBI showed comparable local control
with better long term cosmetic outcome [31].
Intensity modulated radiotherapy (IMRT)
Since inception, IMRT has been promising in achieving excel-
lent dose distribution and organ sparing. It is thus nothing sur-
prising that IMRT would be tried for breast cancer as well.
Due to the fact that the intensity of the beam can be varied
with practically any available angle to direct the beam along
with the facility to either treat with ﬁxed ﬁeld or dynamic tech-
nique, IMRT is deﬁnitely a game changer in modern day
radiotherapy practice. Dosimetric studies have successfully
documented superiority of tangent IMRT compared to 2D
conventional planning or 3DCRT in providing excellent target
coverage, better OAR sparing but at the cost of increased low
dose normal tissue volume, giving rise to future second malig-
nancy risk [32–34]. When these dosimetric approaches were
clinically tested, IMRT showed comparable local control with
less skin toxicity and better cosmesis [35–37]. Signiﬁcant
improvement was noticed in reducing moist dermatitis in these
trials. Breast size was found to be independently associated
with risk of moist dermatitis. Patients having smaller breast
volume and large breast volume were found to have less skin
toxicity compared with medium volume breast, when treated
with IMRT [35,36]. However, the Royal Marsden study
excluded patients with breast volume < 500 cc from receiving
IMRT considering fairly homogenous dose distribution with
standard 2D technique [37]. In another dosimetric study in
postmastectomy patients, tangent IMRT showed better spar-
ing of lung and heart compared with tangent 3DCRT [38].
In a large series of single institute experience with inversely
planned IMRT, Yang and his colleagues have shown good
locoregional control, acute toxicity and acceptable cosmesis
in patients treated with inversely planned IMRT for whole
breast and locoregional irradiation [39]. Large PTV volume
(>520 cc) was signiﬁcantly associated with more acute skin
toxicity.
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of simultaneous integrated boost after BCS. The rationale
behind was requirement of additional boost after whole breast
radiation in many patients. The dosimetric advantage was
enormous with SIB. First of all, it gave the opportunity to look
at the OAR tolerance achievement at the beginning of the
treatment and thus avoiding any future uncertainty. Secondly,
the radiobiology of breast tumor and normal surrounding tis-
sue facilitated hypofractionated treatment, which SIB can
achieve more easily than a sequential boost plan. Thirdly,
the effective duration of treatment could be made shorter com-
pared to prolonged fractionated treatment.
Evidence showing advantage of hypofractionation in pro-
viding adequate locoregional tumor control with comparable
cosmesis helped establishing this simultaneous boost approach
[40–44]. Arc therapy including volumetric modulated arc ther-
apy (VMAT) and Rapid Arc have been also promising
with few clinical studies showing its feasibility and acceptabil-
ity in implementation, tumor control and acute toxicity with
good to acceptable cosmesis in most patients.[45,46] The
RTOG 1005 study will be a giant foot forward in this regard
once the clinical outcome data are published.
Another interesting recent development related with IMRT
for breast cancer is resurgence of internal mammary nodal
(IMN) radiation. With survival advantage in sight, studies
are ongoing to evaluate feasibility of cardiac sparing IMN
radiation and its clinical beneﬁt in postmastectomy and whole
breast radiation [47–50].
Caution must be exercised before implementing this tech-
nique so as to avoid unnecessary and unprecedented high dose
to normal tissues in order to achieve target coverage. The
entire idea of IMRT can backﬁre due to its ‘‘double edged
sword” nature. Rigorous quality assurance, training and
expertize in different aspects of radiation planning starting
from immobilization to treatment veriﬁcation and toxicity
evaluation are crucial.
One less discussed issue about IMRT in breast cancer is
dose received by lung with resulting toxicity. Clinical data
are sparse and immature to comment on the possible late pul-
monary complication developing from a large volume of lung
receiving low dose radiation from inversely planned multiﬁeld
IMRT or arc therapy. The advent of newer techniques every
other year and replacement of the older one is deﬁnitely a
deterrent in assessing the late pulmonary effects of breast radi-
ation with a particular technique which requires many years of
systematic follow up.Stereotactic body radiotherapy (SBRT)
Not very surprisingly, SBRT is also getting its way in ﬁeld of
modern breast radiation oncology. A high dose per fraction
radiation delivered in either single fraction or multiple frac-
tions before conservation surgery for a strictly selective group
of patients showed promising results [51,52]. Like other preop-
erative approach, this has also its advantages of visualizing
intact tumor before it is surgically disturbed, smaller target
volume compared with postoperative target, tumor having
intact blood supply and to add to it, shorter time due to large
dose per fraction. The data of SBRT are not mature enough
and not validated in a large prospective study with long term
follow up in terms of long term disease control and cosmesis.The limited application of this technique within the boundary
of APBI is promising though.
Proton beam therapy
Clinical use of proton beam external radiotherapy in breast
cancer has been on the rise since the last decade. The physical
property of proton beam with its Bragg peak effect gives the
advantage of excellent target coverage with OAR sparing to
a great extent. Depending on the depth and thickness of the
PTV, modulation of proton beam is also possible to generate
adequate dose distribution. Among the different algorithms,
the pencil beam scanning (PBS) proton therapy (PT) provides
best conformity to the tumor. Multiple small pencil beams
cover the tumor in a three dimensional plane. This seems clin-
ically useful with intensity modulation providing greater skin
sparing and adequate coverage of the tumor cavity, while
reducing underlying critical OAR dose Intensity Modulated
Proton therapy (IMPT) has thus become a new way to treat
breast cancer and being implemented both in early breast can-
cer and postmastectomy radiotherapy. Majority of the dosi-
metric work along with few early clinical studies have been
evaluating its role in APBI and chest wall radiotherapy. Car-
diac sparing and skin sparing is excellent in these initial
reports. In a study by Wang and his colleagues, [53] proton
beam APBI was found to generate signiﬁcantly better plan
when compared to photon beam 3DCRT. Absolute reduction
of the mean of V100, V90, V75, V50, and V20 for normal
breast using Passive Scattering Proton Beam (PSPB) was
3.4%, 8.6%, 11.8%, 17.9%, and 23.6%, respectively. For
breast skin, with the similarV90 as 3DCRT photons, the
proton plan signiﬁcantly reduced V75, V50, V30, and V10.
Cardiac and lung doses were also reduced signiﬁcantly with
proton beam.
The same dosimetric advantage was not seen in another
proton beam clinical study [31]. 98 prospective patients with
stage I breast cancer were treated either with photon beam
3DCRT APBI or proton Beam Therapy APBI (PBT APBI).
At 7 years, evaluable patients showed comparable tumor con-
trol with higher rates of long-term telangiectasia, skin color
changes, and other skin toxicities in PBT APBI arm.
The effectiveness of PBS-PT is seen in selective pediatric
intracranial tumor, adult pelvic tumor and post mastectomy
radiotherapy [59–61]. The recently published data from Mas-
sachusetts General Hospital has also proven dosimetric advan-
tage of PBS-PT for postmastectomy radiotherapy using PBS-
PT [61]. Skin dose, cardiac dose and nodal coverage were more
favorable in patients treated with scanning Proton therapy
compared with passive scattering (PS) proton beam.
It will require more time for the proton beam to generate
robust evidence for its routine clinical use in breast radiother-
apy considering available low cost technologies being almost
equal to it in clinical outcome.
Conclusion
External beam radiation in breast cancer has reached a new
horizon. Once dominated by brachytherapy, early stage breast
cancer has also observing increased utilization of newer EBRT
techniques. Availability and progress in technology related to
imaging, treatment delivery and veriﬁcation have made this a
216 D. Mondal, D.N. Sharmarapidly changing subject in the last decade. Whereas the most
important end point, tumor control and survival, has remained
essentially the same, there are increased beneﬁts in terms of
better cosmesis, reduced acute and late radiation morbidity,
reduced long term cardiac morbidity, and reduced patient suf-
fering due to short duration of treatment. All these are perhaps
leading this commonest cancer to have a better survivorship.
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